Studies spotlight misinformation in YouTube bladder and prostate cancer videos
“Our findings highlight an urgent need for more accurate, patient-friendly social media content,” says Dr. Stacy Loeb.
Related Articles
Dr. Salari on family history, germline genetic risk in favorable-risk prostate cancer
“What we found is that over a third of patients, 36%, had positive family history of either prostate, breast, or pancreatic cancer. And if you…
Addition of chemotherapy to ADT improves bPFS in prostate cancer
“Our clinical trial is the first to show a longer time to biochemical recurrence with chemotherapy plus standard hormone therapy for patients with locally advanced,…
Extended coverage expands access to iTind for BPH-related LUTS
iTind is a temporary nitinol device used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia.
Clinical trial program of nadofaragene firadenovec in NMIBC expands
The 3 new additional studies are the ABLE-22, ABLE-32, and ABLE-42 clinical trials.
Dr. Scott Morgan on meta-analysis evaluating prostate RT in mHSPC
“In our analysis, the highest ranked treatment strategy was the combination of standard of care systemic therapy, an AR pathway inhibitor, and prostate radiotherapy,” says…
Conference
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Expert reports on 24-month results of SNM device for OAB
Colin Goudelocke, MD, offers insight on 2 abstracts from the 2024 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting.
Dr. Heidenberg on whether HoLEP study data will influence technique
“I don’t think anybody, at least in our Mayo Clinic practices, is ever doing anything other than apical release HoLEPs these days,” says Daniel J.…
Personalized therapeutic approaches in ccRCC remain challenging
“As a kidney cancer community, we need to investigate these molecular subtypes prospectively in clinical trials to determine whether specific subtypes benefit from certain therapies…
Dr. Shakuri-Rad discusses the da Vinci 5 robotic system
“The da Vinci 5, or DV5, system is the next evolution of robotic surgery,” says Jaschar Shakuri-Rad, DO, FACOS.